Abstract
The first step in killing a tumor cell with a chemotherapeutic agent is to deliver the drug to the cell. Whether the cell is intrinsically sensitive or realtively resistant, the effect of the drug is proportional to the product of its concentration and the duration of exposure. In the case of tumors largely confined to extravascular cavities, such as ovarian carcinoma, there is a legitimate concern that injection of cytotoxic agents intravenously may not be the optimal way to get drug to the tumor. Following intravenous injection, most drugs have ready access to the well vascularized marrow and gut, but because of longer diffusional distances they may have much less access to intraperitoneal tumor. This is analogous to the problem of delivering drug to brain tumors that reside at least partially behind the blood-brain barrier [1]. A number of investigators have tried to improve drug delivery to the tumor by instilling cytotoxic agents directly into the peritoneal cavity, but early studies were done in a limited number of patients using small injection volumes and the results were not particularly exciting [2–4]. However, during the past five years there has been a resurgence of interest in using the intraperitoneal (i.p.) route, spurred initially by work performed at the National Cancer Institute which provided a solid pharmacologic rationale for this approach.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Levin VA, Patlak CS, Landahl MD: Heuristic modelling of drug delivery to malignant brain tumors. J Pharmacokinetics and Biopharmaceutics 8:257–296, 1980.
Weisberger AS, Levine B, Storaasli JP: Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA 159:1704–1707, 1955.
Green TH: Hemisulfer mustard in the palliation of patients with metastatic ovarian carcinoma. Obstet Gynecol 13:383–393, 1959.
Kottmeier HL: Treatment of ovarian carcinomas with thiotepa. Clin Obstet Gynecol 11:428–438, 1968.
Dedrick RL, Myers CE, Bungay PM,DeVita VT, Jr: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treatment Rep 62:1–9, 1978.
Kraft AR, Tompkins RK, Jesseph JE: Peritoneal electrolyte absorption: analysis of portal, systemic venous and lymphatic transport. Surgery 64:148–153, 1968.
Lukas G, Brindle SD, Greengard P: The route of absorption of intraperitoneally administered compounds. J Pharmacol Exp Ther 178:562–566, 1971.
Speyer JL, Sugarbaker PH, Collins JM, Decrick RL, Klecker RW Jr, Myers CE: Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 41:1916–1922, 1981.
Chabner BA, Johns DG, Coleman CN, Drake JC, Evans WH: Purification and properties of cytidine deaminase from normal and leukemic granulocytes. J Clin Invest 53:922–931, 1974.
Howell SB, Chu BCF, Wung WE, Metha BM, Mendelsohn J: Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. J Clin Invest 67:1161–1170, 1981.
Jones RB, Collins JM, Myers CE, Brooks AE, Hubbard SM, Balow JE, Brennan MR, Dedrick RL, DeVita VT: High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Res 41:55–59, 1981.
Pfeifle CE, King ME, Howell SB: Pharmacokinetics and clinical efficacy of intraperitoneal cytarabine treatment of advanced ovarin cancer. Proc Am Soc Clin Oncol 2:150, 1983.
Bulkley GB: Washout of intraperitoneal xenon: effective peritoneal perfusion as an estimation of splanchnic blood flow. In: Granger DN, Bulkley GB (eds) Measurements of Blood Row: Applications to the Splanchnic Circulation. Williams and Wilkins, Baltimore, Chapter 24, pp 441–453, 1981.
Lockhart RD, Hamilton GF, Fyfe FW: Anatomy of the human body. J.B. Lippincott Company, Philadelphia, 1960.
Romanes GB: Editor, Cunningham’s Textbook of Anatomy. Oxford University Press, London 1964.
Leak LV, Rahil K: Permeability of the diaphragmatic mesothelium: the ultrastructural basis for ‘stomata’. Am J Anat 151:577–594, 1978.
Bollman JL, Cain JC, Grindlay JH: Techniques for the collection of lymph from the liver, small intestine, or thoracic duct of the rat. J Lab Clin Med 33:1349–1352, 1948.
Reininger EJ, Saperstein LA: Effect of digestion on distribution of blood flow in the rat. Science 126:1178–0000, 1957.
Torres IJ, Litterst CL, Guarino AM: Transport of model compounds across the peritoneal membrane in the rat. Pharmacology 17:330–340, 1978.
Dedrick RL, Flessner MF, Collins JM, Schults JS: Is the Peritoneum a membrane? Am Soc Artificial Int Organs 5:1–8, 1982.
Nolph KD, Popovich RP, Ghods AJ, Twardowski: Determinants of low clearances of small solutes during peritoneal dialysis. Kid Int 13:117–123, 1978.
Nolph KD: Short dialysis, middle molecules, and uremia. Ann Int Med 86:93–97, 1977.
Maher JF: Principles of dialysis and dialysis of drugs. Am J Med 62:475–481, 1977.
Nolph KD: Peritoneal clearences. J Lab Clin Med 94:519–525, 1979.
Maher JF: Peritoneal transport rates: Mechanisms, limitation and methods for augmentation. Kid Int 18:117–120, 1980.
Holcenberg J, Anderson T, Ritch P, Skibba J, Howser D, Ring B, Adams S, Helmswoth M: Intraperitoneal chemotherapy with melphalan plus glutaminase. Cancer Res 43:1381–1388, 1983.
Burchenal JH, Kalaher K, Dew K, Lokys L, Gale G: Studies of cross-resistance, synergistic combinations and blocking of activity of platinum derivaties. Biochimie 60:961–965, 1978.
LeRoy AF, Lutz RJ, Dedrick RL, Litterst CL, Guarino AM: Pharmacokinetic study of cis-dichlorodiammineplatinum (II) (DDP) in the beagle dog: thermodynamic and kinetic behavior of DDP in a biologic milieu. Cancer Treatment Rep 63:59–70, 1979.
Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ, Sternson LA: Clinical kinetics of intact cisplatin and some related species. Clin Pharmacol Ther 29:658–664, 1981.
Speyer JL, Collins JM, Dedrick RL, Brennan MF, Buckpitt AR, Londer H, DeVita VT Jr, Myers CE: Phase I pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 40:567–672, 1980.
Howell SB, Wung WE, Taetle R, Hussain F, Romine JS: Modulation of 5-fluorouracil toxicity by allopurinol in man. Cancer 48:1281–1289, 1981.
Slevin ML, Piall EM, Aherne GW, Johnston A, Lister TA: The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high dose therapy. Medical and Pediatric Oncology Supplement 1:157–168, 1982.
Howell SB, Pfeifle CE, Wung WE, Olshen RA, Lucas WE, Yon JL, Green M: Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97:845–851, 1982.
Alberts DS, Chang SY, Chen H-SG, Moon TE, Evans TL, Furner RL, Himmelstein K, Gross JF: Kinetics of intravenous melphalan. Clin Pharmacol Ther 26:73–80, 1979.
Pfeifle CE, Howell SB, Olshen RA, Wung WE: Intraperitoneal melphalan: A phase I study. Am Soc Clin Pharm Therap 33:223, 1983.
Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE: Plasma pharmacokinetics of adriamycin and adriamycinol: Implications for the design of in vitro experiments and treatment protocols. Cancer Research 43:3417–3421, 1983.
Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Green R, Jenkins J, Myers CE: Phase I and pharmacological studies of adriamycin administered intraperitonelly to patients with ovarian cancer. Cancer 42:4265–4269, 1982.
Jones RB, Myers CE, Guarino AM, Dedrick RL, Hubbard SM, DeVita VT: High volume intraperitoneal chemotherapy (‘belly bath’) for ovarian cancer. Cancer Chemother Pharmocol 1:161–166, 1978.
Katz ME, Schwartz PE, Kapp DS, Luikart S: Epithelial carcinoma of the ovary: current strategies. Ann Int Med 95:98–111, 1981.
Tully TE, Goldberg ME, Loken MK: The use of 99mTc-sulfur colloid to assess the distribution of 32P chromic phosphate. J Nucl Med 15:190–191, 1974.
Taylor A Jr et al.: Loculation as a contraindication to intracacitary 32P chromic phosphate therapy. J Nucl Med 16:318–319, 1975.
Vider M, Deland Fm, Maruyama Y: Loculation as a contraindication to intracavitary 32P chromic phosphate therapy. J Nucl Med 17:150–151, 1976.
Rosenshein N, Blake D, Mclntyre PA, Parmley T, Natarajan TK, Dvornicky J, Nickoloff E: The effect of volume on the distribution of substances instilled into the peritoneal cavity. Gynecologic Oncology 6:106–110, 1978.
Dunnick NR, Jones RB, Doppman JL, Speyer J, Myers CE: Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics. AJR 133:221–223, 1979.
West GW, Weichselbau R, Little JB: Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res 40:3668, 1980.
Durand RE: Row cytometry studies of intracellular adriamycin in multicell spheroids in vitro. Cancer Res 41:3495–3498, 1981.
Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC: Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 39:3209–3214, 1979.
Fenstermacher JD, Patlak CS, Blasberg RG: Transport of material between brain extracellular fluid, brain cells and blood. Federation Proceedings 33 (9): 2070–2074, 1974.
Blasberg RG, Patlak C, Fenstermacher JD: Intrathecal chemotherapy: Brain tissue profiles after ventriculocisternal perfusion. J Pharmacology & Experimental Therapeutics 195(l):73–83, 1975.
Blasberg RG, Patlak CS, Shapiro WR: Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. Cancer Treatment Reports 61:633–641, 1977.
Collins JM, Dedrick RL, Flessner MF, Guarino AM: Concentration-dependent disappearance of fluorouracil from peritoneal fluid in the rat: Experimental observations and distributed modeling. J Pharma Sci 71(7): 735–738, 1982.
Collins JM, Dedrick RL, King FG, Speyer JL, Myers CE: Non-linear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharmacol Ther pp 235–246, 1980.
Howell SB, Pfeifle CE, Wung WE, Olshen RA: Intraperitoneal cisplatin with systemic thiosulfate protection. Cancer Res 43:1426–1431, 1983.
Ostrowski MJ, Halsall GM: Intracavitary bleomycin in the management of malignant effusions: A multicenter study. Cancer Treat Rep 66:1903–1907, 1982.
Alberts DS, Chen H-SC, Chang SY, Peng YM: The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients. Recent Results in Cancer Research 74:293–299, 1980.
Alberts DS, Chen H-SG, Mayersohn M, Perrier D, Moon TE, Gross JF: Bleomycin pharmacokinetics in man. Cancer Chemother Pharmacol 2:127–132, 1979.
Speyer JL, Myers CE: The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies. Recent Results in Cancer Research 74:264–269, 1980.
Ozols RF, Grotzinger KR, Fisher RI, Myers CE, Young RC: Kinetic characterization and response to chemotherapy in a transplantable murine ovarian cancer. Cancer Res 39:3202–3208, 1979.
Schwartz HS: A fluorometric assay for daunomycin and adriamycin in animal tissues. Biochemical Medicine 7:396–404, 1973.
Donelli MG, Martini A, Colombo T, Bossi A, Garattini S: Heart levels of adriamycin in normal and tumor-bearing mice. Europ J Cancer 12:913–923, 1976.
Howell SB, Taetle R: Effect of sodium thiosulfate on cis-Dichlorodiammineplatinum (II) toxicity and antitumor activity in L1210 leukemia. Cancer Treat Rep 64(4–5):616–616, 1980.
Casper ES, Kelson DP, Alcock NW, Lewis JL, Jr: Ip cisplatin in patients with malignant ascites: Pharmacokinetic evaluation and comparison with the i.v. route, cancer Treat Rep 67(3): 235–238, 1983.
Wasserman TH, Comis RL, Goldsmith M, et al.: Tabular analysis of the clinical chemotherapy of solid tumors. Cancer Chemother Rep 6(3):399–419, 1975.
Ho DH, Frei E3rd: Clinical pharmacology of 1-beta-D-arabinofuranosyl cytosine. Clin Pharmacol Ther 12:944–954, 1971.
King ME, Pfeifle CE, Markman M, Howell SB: Cytarabine pharmacokinetics following intraperitoneal administration. Clin Pharmacol Ther 33:222, 1983.
Vistica DT, Von Hoff DD, Torain B: Uptake of melphalan by human ovarian carcinoma cells and its relationship to the amino acid content of ascitic fluid. Cancer Treat Rep 65(1–2): 157–161, 1981.
Holcenberg J, Anderson T, Ritch P, Skibba J, Howser D, Ring B, Adams S, Helmsworth M: Intraperitoneal chemotherapy with melphalan plus glutaminase. Cancer Res 43:1381–1388, 1983.
Gyves J, Ensminger W, Niederhuber J, Manuzak P, Van Harken D, Janis MA, Stetson P, Knutsen C, Doan K: Phase I study of intraperitoneal (IP) 5 day continuoua 5-FU infusion and bolus mitomycin C. Proc ASCO 1:15, 1982.
Gianni L, Jenkins JF, Greene RF, Lichter AS, Myers CE, Collins JM: Pharmacokinetics of the hypoxic radiosensitizers misonidazole and demethylmisonidazole after intraperitoneal administration in humans. Cancer Res 43:913–916, 1983.
Stratford IJ, Adams GE, Horsman MR, Kandaiya S, Rajartnam S, Smith E, Williamson C: The interaction of misonidazole with radiation, chemotherapeutic agents, or heat. Cancer Clin Trials 3:231–236, 1980.
Goldie JH, Coltman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727–1733, 1979.
Goldie JH, Coldman AJ, Gudauskas GA: Rationale for the use of alternating non-crossresistant chemotherapy. Cancer Treat Rep 66(3): 439–449, 1982.
Young RC, Chabner BA, Hubbard SP, Fisher RI, Bender RA, Anderson T, Simon RM, Canellos GP, DeVita, VT: Advanced ovarian adenocarcinoma: A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med 299:1261–1266, 1978.
Gershenson DM, Wharton JT, Herson J, Edwards CL, Rutledge FN: Single-agent cis-Platinum therapy for advanced ovarian cancer. Obstet Gynecol 58(4): 487–496, 1981.
Williams CJ, Mead B, Arnold A, Green J, Buchanan R, Whitehouse M: Chemotherapy of advanced ovarian carcinoma. Cancer 49:1778–1783, 1982.
Cohen CJ, Goldberg JD, Holland JF, Bruckner HW, Deppe G, Gusberg SB, Wallach RC, Kabakow B, Rodin J: Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation). Am J Obstet Gynecol 145:955–967, 1983.
Drewinko B, Green Catherine, Loo TL: Combination chemotherapy in vitro with cis-dichlorodiammineplatinum (II). Cancer Treat Rep 60(11): 1619–1625, 1976.
Bergerat J-P, Green C, Drewinko B: Combination chemotherapy in vitro. IV. response of human colon carcinoma cells to combinations using cis-diamminedichloroplatinum. Cancer Biochem Biophy 3:173–180, 1979.
Bergerat J-P, Drewinko B, Corry P, Barlogie B, Ho DH: Synergistic lethal effect of cis-dichorodiammineplatinum and 1-Beta-D-arabinofuranosylcytosine. Cancer Res 41:25–30, 1981.
Markman M, Green MR, Pfeifle CE, Lucas WE, Yon JL, Howell SB: Combination intracavitary chemotherapy in patients with stage III–IV ovarian carcinoma failing standard treatment regimens. Proc ASCO 2:147, 1983.
Vaughan WP, Burke PJ: Development of a cell kinetic approach to curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-beta-d-arabinofuranosylcytosine in a rat model. Cancer Res 43:2005–2009, 1983.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Martinus Nijhoff Publishers, Boston
About this chapter
Cite this chapter
Markman, M., Howell, S.B. (1985). Intraperitoneal chemotherapy for ovarian carcinoma. In: Alberts, D.S., Surwit, E.A. (eds) Ovarian Cancer. Cancer Treatment and Research, vol 23. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2561-1_9
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2561-1_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9609-6
Online ISBN: 978-1-4613-2561-1
eBook Packages: Springer Book Archive